On October 16, 2025 Rakovina Therapeutics Inc. ("Rakovina" or the "Company") (TSX-V: RKV, FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, reported that new preclinical data from its ATR inhibitor program will be presented in a poster session at the upcoming AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), held October 22-26 at the Hynes Convention Center Boston, Massachusetts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DNA damage repair (DDR) enzymes, including Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR), are crucial for maintaining stability in cells. Inhibition of DDR enzymes has proven to be a compelling therapeutic option for numerous cancer indications. However, they lack the ability to effectively penetrate through the blood-brain barrier into the central nervous system (CNS), making them suboptimal for the treatment of brain tumors and metastases.

Rakovina’s presentation will highlight the Company’s ATR inhibitor program developed in collaboration with Variational AI and their Enki generative AI platform. This platform was used to create a shortlist of compounds with properties to selectively target ATR. The most promising molecules from this list were synthesized and characterized in vitro and in vivo. Data on the potency, selectivity, CNS penetrance and metabolic stability of select inhibitors will be presented and members of the team will be available for discussion with potential collaborators.

"The data to be presented at AACR (Free AACR Whitepaper)-NCI-EORTC reflects the continued progress of our AI-driven drug discovery pipeline and the importance of our collaboration with Variational AI," said Prof. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics. "Our ATR inhibitor drug candidates show strong efficacy and blood-brain barrier permeability, a critical unmet need in current cancer therapies."

Presentation Details:

Title: Novel ATR inhibitors with CNS penetrance developed by artificial intelligence
Presentation Date: Poster session C, Saturday, October 25, 12:30 – 4 pm ET

(Press release, Rakovina Therapeutics, OCT 16, 2025, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-to-present-new-data-highlighting-novel-atr-inhibitor-with-cns-penetration-at-the-aacr-nci-eortc-international-conference [SID1234656707])

On October 16, 2025 Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, reported it will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025, at 4:00 p.m. ET. The webcast will feature updates from leading experts on recent clinical progress and expanding international access for its immunotherapy combination botensilimab (BOT) and balstilimab (BAL). The session will be moderated by Garo Armen, PhD, Founder, Chairman, and CEO, and conclude with a live Q&A.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Featured Topics and Speakers

Expanding Immunotherapy’s Reach: ESMO (Free ESMO Whitepaper) 2025 Highlights
Michael S. Gordon, MD, HonorHealth Research Institute

Dr. Gordon will discuss results from his oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025, featuring data from over 400 patients treated with BOT/BAL across multiple refractory solid tumors.

Access Beyond Borders: France’s Autorisation d’Accès Compassionnel (AAC) Program and BOT/BAL’s Inclusion
Alexander M.M. Eggermont, MD, PhD, world-renowned immuno-oncologist and former Director General of the Gustave Roussy Cancer Center in France

Professor Eggermont will provide perspective on the French AAC program and its implications for oncologists and patients living with refractory MSS colorectal cancer.
Stakeholder Briefing Details:

Webcast Link | View Source
Pre-registration is not required.

This session marks the second in Agenus’ 2025 Stakeholder Briefing Series, following the August event highlighting corporate strategy, clinical milestones, and the launch of the global Phase 3 BATTMAN trial. A third session will follow in November, continuing the dialogue on BOT/BAL’s progress and corporate milestones.

(Press release, Agenus, OCT 16, 2025, View Source [SID1234656709])

On October 16, 2025 OmniAb, Inc. (NASDAQ: OABI) reported that management will be participating in three investor conferences during the month of November.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2025 Truist Securities BioPharma Symposium, November 6 at the Lotte New York Palace Hotel. Matt Foehr, Chief Executive Officer, will participate in one-on-one meetings with investors on Thursday, November 6 th.
Stifel 2025 Healthcare Conference, November 11-13 at the Lotte New York Palace Hotel. Kurt Gustafson, Chief Financial Officer, will participate in one-on-one meetings with investors on Wednesday, November 12 th.
Jefferies Global Healthcare Conference – London, November 17-20 at the Waldorf Hilton. Matt Foehr, Chief Executive Officer, will present a corporate overview on Wednesday, November 19 th at 8:00 a.m. GMT and will hold one-on-one and small-group meetings with investors on November 18-19.

(Press release, OmniAb, OCT 16, 2025, View Source [SID1234656710])

On October 16, 2025 Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, reported the signing of a Supply Agreement for copper-67 with Nusano, Inc. ("Nusano").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nusano’s 190,000 square foot state-of-the-art facility in West Valley City, Utah is expected to begin operations in late 2025 with copper-67 isotope supply planned to commence in mid-2026. The proprietary accelerator-based technologies employed by Nusano are particularly well suited for high-volume mass production of copper-67. Nusano is uniquely positioned to regularly supply this therapeutic isotope for both Clarity’s clinical trials and commercial use based on the ease of production and readily available target material. Importantly, Nusano is setting up its own enriched stable isotope production for copper-67 starting materials in the near future, further reducing supply chain risks while allowing for a fully integrated production process in the United States.

The copper-67 supply from Nusano further expands Clarity’s growing network of US-based suppliers, including NorthStar Medical Radioisotopes, LLC ("NorthStar") and Idaho State University Idaho Accelerator Center (IAC).

Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, commented: "We are excited to continue growing our supply network for copper-67 in preparation for a registrational Phase III clinical trial with 67Cu-SAR-bisPSMA, our lead product aimed at improving the treatment paradigm for men suffering with prostate cancer. With outstanding preliminary clinical trial data generated to date from our Phase I/IIa SECuRE trial and a Fast Track Designation in the US for this optimised product, we look forward to progressing our theranostic program, pending final study findings.

"Building reliable, abundant, sustainable and cost-effective supply goes hand-in-hand with our clinical development to allow us to swiftly scale manufacturing when needed. We have seen in the past the challenges associated with growing isotope supply with lutetium-177, which relies heavily on an ageing fleet of nuclear reactors, ultimately affecting care for oncology patients waiting for their treatments. We believe, the shift away from limited nuclear reactor-based supply to more easily scalable accelerator-based methods is a prerequisite for radiopharmaceuticals to grow sustainably into the large oncology sector. By employing copper-67, we can avoid many of the drawbacks of other therapeutic isotopes. Its production requires only electricity and readily available starting materials. With Nusano’s alternative production methods, we are further differentiating our supply and look forward to having numerous pathways to producing large quantities of copper-67."

Nusano’s Chief Executive Officer, Chris Lowe, commented: "Nusano is commercialising a breakthrough radioisotope production platform in 2025 capable of producing more than 25 radioisotopes for life science applications. We are excited to deepen our relationship with Clarity through the signing of this Supply Agreement for copper-67 to enable their clinical and commercial efforts with a dependable supply of radioisotopes from our world-class production facility in Utah.

"Clarity is in a unique position with their copper-67 program, being the only radiopharmaceutical company with ongoing clinical trials utilising this important isotope, and we look forward to working together as they continue to progress their program toward registrational trials and commercialisation."

Additional Disclosure
The Supply Agreement is effective as of 16 October 2025 and is for an initial period of 3 years with automatic renewal for successive 2-year periods. Cancellation provisions are aligned with industry standard rates.

(Press release, Clarity Pharmaceuticals, OCT 16, 2025, View Source [SID1234656673])

On October 16, 2025 4SC AG (4SC, FSE Prime Standard: VSC) reported its Q3-Report 2025, presenting all material developments up to 30 September 2025, as well as the Company’s current outlook. The full report is available for download on 4SC’s website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Development of cash balance in Q3 2025 and financial forecast
As of 30 September 2025, 4SC holds cash balance/funds of €4,742 thousand as compared to €8,311 thousand as of 31 December 2024. The Management Board believes that the Company’s available cash and cash equivalents are sufficient to either:

in combination with a successful completion of the capital increase, result in sufficient cash for a transitional period to allow the Company at least until the end of 2026 to find a new business (as described in the invitation to the Company’s most recent AGM on 19 September 2025), or
cover the projected costs for an orderly liquidation if this could be completed by the end of Q1 2027. In the event of the Company being liquidated, the Management Board expects that 4SC will, at best, be able to repay a portion of the outstanding subordinated shareholder loans with no liquidation surplus for distribution to 4SC’s shareholders.

(Press release, 4SC, OCT 16, 2025, View Source [SID1234656711])